Use of concomitant azoles (safety analysis set)
| . | Patients with SR-aGVHD [REACH2] (n=302) . | Patients with SR-cGVHD [REACH3] (n=323) . | ||
|---|---|---|---|---|
| Ruxolitinib (n = 152) . | BAT (n = 150) . | Ruxolitinib (n = 165) . | BAT (n = 158) . | |
| Triazole derivatives, n (%) | 117 (77.0) | 106 (70.7) | 116 (70.3) | 102 (64.6) |
| Posaconazole | 79 (52.0) | 69 (46.0) | 48 (29.1) | 54 (34.2) |
| Voriconazole | 38 (25.0) | 22 (14.7) | 38 (23.0) | 20 (12.7) |
| Fluconazole | 18 (11.8) | 17 (11.3) | 40 (24.2) | 39 (24.7) |
| Isavuconazole | 7 (4.6) | 6 (4.0) | 4 (2.4) | 4 (2.5) |
| Itraconazole | 7 (4.6) | 7 (4.7) | 5 (3.0) | 2 (1.3) |
| Isavuconazonium sulfate | 1 (0.7) | 2 (1.3) | 2 (1.2) | 3 (1.9) |
| Fosfluconazole | 2 (1.3) | 0 | 1 (0.6) | 0 |
| . | Patients with SR-aGVHD [REACH2] (n=302) . | Patients with SR-cGVHD [REACH3] (n=323) . | ||
|---|---|---|---|---|
| Ruxolitinib (n = 152) . | BAT (n = 150) . | Ruxolitinib (n = 165) . | BAT (n = 158) . | |
| Triazole derivatives, n (%) | 117 (77.0) | 106 (70.7) | 116 (70.3) | 102 (64.6) |
| Posaconazole | 79 (52.0) | 69 (46.0) | 48 (29.1) | 54 (34.2) |
| Voriconazole | 38 (25.0) | 22 (14.7) | 38 (23.0) | 20 (12.7) |
| Fluconazole | 18 (11.8) | 17 (11.3) | 40 (24.2) | 39 (24.7) |
| Isavuconazole | 7 (4.6) | 6 (4.0) | 4 (2.4) | 4 (2.5) |
| Itraconazole | 7 (4.6) | 7 (4.7) | 5 (3.0) | 2 (1.3) |
| Isavuconazonium sulfate | 1 (0.7) | 2 (1.3) | 2 (1.2) | 3 (1.9) |
| Fosfluconazole | 2 (1.3) | 0 | 1 (0.6) | 0 |
aGVHD, acute graft-versus-host disease; BAT, best available therapy; cGVHD, chronic graft-versus-host disease; SR, steroid refractory.